论文部分内容阅读
目的观察低剂量重组改构人肿瘤坏死因子(rmh TNF)联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法选取重庆市中医院2014年5月—2015年6月收治的80例晚期NSCLC患者。随机分为试验组48例和对照组32例。试验组给予rmh TNF联合化疗方案治疗,对照组给予单纯化疗,两组均采用NP、TP方案化疗。比较两组患者的临床疗效及毒副作用发生情况。结果试验组有效率为33.3%,高于对照组的21.9%,差异有统计学意义(P<0.05)。治疗前两组患者KPS评分比较,差异无统计学意义(P>0.05);治疗后试验组KPS评分高于对照组,差异有统计学意义(P<0.05)。结论静脉滴注低剂量的rmh TNF联合化疗药物治疗NSCLC的近期疗效理想,可显著改善患者的生活质量。
Objective To observe the clinical effect of low dose recombinant rmh TNF combined with chemotherapy on advanced non-small cell lung cancer (NSCLC). Methods Eighty patients with advanced NSCLC who were treated in Chongqing Traditional Chinese Medicine Hospital from May 2014 to June 2015 were selected. Randomly divided into experimental group of 48 cases and control group of 32 cases. The experimental group was given rmh TNF combined with chemotherapy regimen, the control group was given chemotherapy alone, both groups were treated with NP, TP regimen. The clinical efficacy and side effects of the two groups were compared. Results The effective rate of the experimental group was 33.3%, higher than that of the control group (21.9%), the difference was statistically significant (P <0.05). There was no significant difference in KPS score between the two groups before treatment (P> 0.05). The KPS score of the experimental group after treatment was higher than that of the control group (P <0.05). Conclusion Intravenous infusion of low dose of rmh combined with chemotherapy drugs for the treatment of NSCLC ideal short-term effect, can significantly improve the quality of life of patients.